The Global Health Body Issues Concern Over Severe Lack of Obesity Jabs
Less than 10% of people who could benefit from obesity jabs including Wegovy have access to them, states the global health agency as it publishes its first recommendations on the medications.
Given more than one billion individuals worldwide now obese, it is urging increased and just availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The new guidelines affirms that obesity is a chronic disease that can be treated with thorough and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major obstacles to broad availability to the treatments that can aid individuals in losing considerable weight, explains the body.
Weight-Loss Drug Shortage
Even in the current most optimistic scenario, the manufacturing of these medications would only suffice for approximately 100 million people – under 10% of the global need, according to the health organization.
The recommendation calls on governments and firms to expand access, through measures like licensing agreements.
The intellectual property rights on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
The Way Obesity Drugs Operate
GLP-1 drugs mimick a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals eat less.
People typically begin shedding pounds in the initial weeks of beginning the regular doses.
Studies indicates users may put most of the weight back on after a year of halting the medication, as their normal hunger come back.
Being carrying excess weight raises your chance for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity impacts individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, as per the health agency.
